A scientist studying pain processing in a mouse model administers a drug that inhibits proteolytic processing of proopiomelanocortin (POMC) in the pituitary. An increased response to painful stimuli is noted in the treated animals compared to controls. The effect of the drug is due to a lack of effective levels of Group of answer choices β-endorphin ACTH Growth Hormone α-melanocyte-stimulating hormone (α-MSH)

A scientist studying pain processing in a mouse model administers a drug that inhibits proteolytic processing of proopiomelanocortin (POMC) in the pituitary. An increased response to painful stimuli is noted in the treated animals compared to controls. The effect of the drug is due to a lack of effective levels of Group of answer choices β-endorphin ACTH Growth Hormone α-melanocyte-stimulating hormone (α-MSH)

Human Physiology: From Cells to Systems (MindTap Course List)

9th Edition

ISBN:9781285866932

Author:Lauralee Sherwood

Publisher:Lauralee Sherwood

Chapter4: Principles Of Neural And Hormonal Communication

Section: Chapter Questions

Problem 18RE

See similar textbooks

Similar questions

Explain how mutations in the following proteins might result in either loss of responsiveness to a given hormone or production of a continuous signal even in the absence of the hormone: a mutation in the regulatory (R) subunit of cAMP-dependent protein kinase, making R incapable of binding to the catalytic (C) subunit
Two GPCR mutations (Mutant A and Mutant B) were tested for activity. One was confirmed as being a constitutively activating, gain of function GPCR mutation and one was confirmed as being a loss of function GPCR mutation. Which is which? Explain your answer.
There can be more than one answer
Recently, a Gα q-coupled receptor was discovered that mediates at least some of the many activities of estrogen. At the time, this discovery generated considerable controversy, as it ran counter to what was then the understanding of how steroid hormone signaling worked. Which of the following observations might have led the investigators to suspect the existence of this newly discovered receptor? A. Activities of estrogen apparent less than 1 minute after application of the hormone B. The growth promoting activity of estrogen C. The presence of estrogen nuclear receptors in cells not previously known to respond to the hormone D. Estrogen is found in much higher concentrations in adult women than adult men E. Uptake of estrogen by target cells
Overexpression of this receptor in the cells of the adrenal gland causes Cushing's syndrome, a disease caused by the overproduction of cortisol. One strategy that scientists have employed to treat this disease is the use of small molecules that bind to, but do not activate, MC2R. This type of molecule is generically referred to as an antagonist. How can an antagonist bind to the same receptor as ACTH but not activate it? O a. The antagonist can bind covalently while ACTH binds non-covalently O b. The antagonist is only partially complimentary to the binding pocket of MC2R O The antagonist binds to ACTH and blocks it from binding to the receptor properly O d. The antagonist is the exact same structure as ACTH but since it is synthetic it doesn't work One cause of Cushing's syndrome is the inappropriate production of GPCRS in the adrenal gland that are not normally present in those cells. When these receptors are activated they result in the production of cortisol. Which statement about…
All the B - adrenergic receptors are linked with Gs G-protein. Physiological processes mediated by the intracellular second messenger cyclic AMP include: YOU CAN CHOOSE MORE THAN ONE A.carbohydrate breakdown by the liver (glycogenolysis) B.increased contractility (e.g. increased cardiac contractility) C.smooth muscle relaxation (e.g. bronchodilation or vasodilation) D.Triglyceride breakdown (lipolysis)
In a cell line derived from normal rat thyroid, stimulation of the alpha1-adrenergic receptor increases both IP3 formation and release of arachidonic acid (AA). IP3 elevates cytosolic Ca, which mediates thyroxine efflux, whereas AA serves as a source of prostaglandin E2, which stimulates DNA synthesis. It is not clear how AA release is connected to the adrenergic receptor. AA could arise by cleavage from the DAG that accompanies IP3 production. Alternatively, AA could arise through an independent effect of the receptor on PLA2, which can directly release AA from intact phosphoglycerides. Consider the following experimental observations: a) Addition of noradrenaline to cell cultures stimulates production of both IP3 and AA. b) If the alpha1-adrenergic receptors are made unresponsive to noradrenaline by treatment with phorbol esters (which act through PKC to cause phosphorylation, and inactivation, of the receptor), addition of noradrenaline causes no increase in IP3 or AA. c) When…
Under in vivo conditions, chronic treatment with a noncompetitive antagonist may lead to the up-regulation of the targeted receptor over time. True False Cytokines are peptides that are generally made in advance by specific types of cells, stored in vesicles, and act as autocrine or paracrine factors. True False Thyroid hormone is stored in an extracellular compartment. True False
Identify the partial sequence of events that occurs after the insulin binds to its receptor. 1. Phosphorylation of insulin receptor substrate (IRS-1) 2. Activation of the receptor tyrosine kinase activity 3. Activation of phosphodiesterase 4. Activation of phospholipase C 5. Phosphorylation of phosphatidylinositol 6. Activation of phosphatidylinositol-3 -kinase (P1-3 kinase) 7. Binding of Grb 2 8. Activation of a phosphatase 9. Dephosphorylation of pyruvate kinase 10. phosphorylation of pyruvate kinase 2-7-1-4-3-9 1-7-3-5-6-8 2-1-6-5-8-9 2-7-1-6-5-8-9 2-7-4-6-1-8-10
Buprenorphine is a partial agonist at mu opioid receptors and is used for opioid maintenance treatment (OMT) in patients with opioid use disorder (OUD). Buprenorphine is formulated in a product that contains the mu opioid receptor antagonist, naloxone. What is the purpose of naloxone in this formulation? O To increase the magnitude of response to the partial agonist. O To reduce the likelihood that buprenorphine will be injected intravenously. O To delay the response to buprenorphine. O To provide pain relief to the patient who has OUD.
Using the cultured cells used in this experiment and described in the introduction, how would you approach determining the potency of an agonist to the D2 receptor?
List examples of paracrine chemical messengers that playa role in modulating pain or are peptide growth factors.